Immunovant's IMVT-1402 600 mg meets primary endpoint in rheumatoid arthritis trial, plans FDA talks.

Immunovant reported that its drug IMVT-1402 600 mg achieved the primary endpoint of ACR20 response at Week 28 in a trial for difficult-to-treat rheumatoid arthritis, showing significant improvement over placebo. Exploratory results also showed increasing ACR50 and ACR70 responses. The company plans to discuss the next steps with the FDA later this year. Financially, Immunovant ended the quarter with $722.3 million in cash and reduced net loss compared to the prior year, while continuing clinical development in other autoimmune diseases.

Immunovant's stock price is currently at USD 30.01 on Pluang, down 1.70% in the last day. As of Nov 09, 2026 19:02 WIB, the company holds a market cap of $6.31 billion with a trading volume of 2,658,533 shares.